{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:21:18Z","timestamp":1794961278692,"version":"4.9.1"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005297","name":"Medical University of Bialystok","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005297","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.neuropharm.2025.110402","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T11:10:21Z","timestamp":1741345821000},"page":"110402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes"],"prefix":"10.1016","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2448-1190","authenticated-orcid":false,"given":"Stefan","family":"Modzelewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Stankiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Napoleon","family":"Waszkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9413-3976","authenticated-orcid":false,"given":"Kacper","family":"\u0141ukasiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2025.110402_bib1","doi-asserted-by":"crossref","DOI":"10.1177\/2050324520974484","article-title":"2019: a year of expansion in psychedelic research, industry, and deregulation","volume":"6","author":"Aday","year":"2020","journal-title":"Drug Science, Policy and Law"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110402_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-024-02900-4","article-title":"LSD increases sleep duration the night after microdosing","volume":"14","author":"Allen","year":"2024","journal-title":"Transl. Psychiatry"},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110402_bib3","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S0006-3223(96)00548-3","article-title":"The altman self-rating Mania scale","volume":"42","author":"Altman","year":"1997","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110402_bib4","doi-asserted-by":"crossref","DOI":"10.1186\/s12954-019-0308-4","article-title":"Psychedelic microdosing benefits and challenges: an empirical codebook","volume":"16","author":"Anderson","year":"2019","journal-title":"Harm Reduct. J."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110402_bib5","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00213-018-5106-2","article-title":"Microdosing psychedelics: personality, mental health, and creativity differences in microdosers","volume":"236","author":"Anderson","year":"2019","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110402_bib6","doi-asserted-by":"crossref","DOI":"10.1186\/s12954-019-0333-3","article-title":"Twenty percent better with 20 micrograms? A qualitative study of psychedelic microdosing self-rapports and discussions on YouTube","volume":"16","author":"Andersson","year":"2019","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.neuropharm.2025.110402_bib7","series-title":"RollingStone","article-title":"How LSD microdosing became the hot new business trip","author":"Andrew","year":"2015"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110402_bib8","first-page":"461","article-title":"Preliminary report on the effects of a low dose of LSD on resting-state amygdala functional connectivity","volume":"5","author":"Bershad","year":"2020","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110402_bib9","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.biopsych.2019.05.019","article-title":"Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers","volume":"86","author":"Bershad","year":"2019","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110402_bib10","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/20494637221114962","article-title":"Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey","volume":"16","author":"Bonnelle","year":"2022","journal-title":"Br. J. Pain"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110402_bib11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1024465317902","article-title":"Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS)","volume":"11","author":"Bremner","year":"1998","journal-title":"J. Trauma Stress"},{"key":"10.1016\/j.neuropharm.2025.110402_bib12","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.66920","article-title":"Citizen science asking questions of psychedelic microdosing","volume":"10","author":"Cameron","year":"2021","journal-title":"Elife"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110402_bib13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/02791072.2020.1718250","article-title":"Psychedelic microdosing: prevalence and subjective effects","volume":"52","author":"Cameron","year":"2020","journal-title":"J. Psychoact. Drugs"},{"issue":"19","key":"10.1016\/j.neuropharm.2025.110402_bib14","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1016\/j.neuron.2022.08.006","article-title":"Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSD","volume":"110","author":"Cao","year":"2022","journal-title":"Neuron"},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110402_bib15","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/npp.2017.84","article-title":"The therapeutic potential of psychedelic drugs: past, present, and future","volume":"42","author":"Carhart-Harris","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110402_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13143","article-title":"Repeated low doses of LSD in healthy adults: a placebo-controlled, dose\u2013response study","volume":"27","author":"de Wit","year":"2022","journal-title":"Addict. Biol."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110402_bib17","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/02791072.2020.1847366","article-title":"Persistent tinnitus after inhaled N,N-dimethyltryptamine (DMT)","volume":"53","author":"Diab","year":"2021","journal-title":"J. Psychoact. Drugs"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110402_bib18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/03602532.2016.1278228","article-title":"Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance","volume":"49","author":"Dinis-Oliveira","year":"2017","journal-title":"Drug Metab. Rev."},{"issue":"Suppl. 2","key":"10.1016\/j.neuropharm.2025.110402_bib19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-2007-979351","article-title":"The standardized psychometric assessment of altered states of consciousness (ASCs) in humans","volume":"31","author":"Dittrich","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.neuropharm.2025.110402_bib20","series-title":"DMT Is Giving Me Tinnitus","year":"2017"},{"key":"10.1016\/j.neuropharm.2025.110402_bib21","series-title":"The Psychedelic Explorer's Guide: Safe, Therapeutic, and Sacred Journeys","author":"Fadiman","year":"2011"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110402_bib22","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/02791072.2019.1593561","article-title":"Might microdosing psychedelics Be safe and beneficial? An initial exploration","volume":"51","author":"Fadiman","year":"2019","journal-title":"J. Psychoact. Drugs"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110402_bib23","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00213-019-05417-7","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers","volume":"237","author":"Family","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110402_bib24","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.neuropharm.2025.110402_bib25","series-title":"FDA Rejects MDMA as a Psychedelic Treatment for PTSD","author":"Goldhill","year":"2024"},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110402_bib26","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110402_bib27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0269881117731279","article-title":"Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors","volume":"32","author":"Griffiths","year":"2018","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110402_bib28","doi-asserted-by":"crossref","first-page":"e1230","DOI":"10.1002\/cl2.1230","article-title":"An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell Syst Rev"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110402_bib29","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00005053-196509000-00006","article-title":"Addiction Research Center Inventory (ARCI): development of a general drug estimation scale","volume":"141","author":"Haertzen","year":"1965","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.neuropharm.2025.110402_bib30","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3389\/fphar.2018.00897","article-title":"Predicting responses to psychedelics: a prospective study","volume":"9","author":"Haijen","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"7969","key":"10.1016\/j.neuropharm.2025.110402_bib31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/d41586-023-02093-8","article-title":"Australia to prescribe MDMA and psilocybin for PTSD and depression in world first","volume":"619","author":"Haridy","year":"2023","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110402_bib32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","article-title":"Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study","volume":"172","author":"Hasler","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"issue":"3\u20134","key":"10.1016\/j.neuropharm.2025.110402_bib33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.peh.2019.01.001","article-title":"Descriptive assemblage of psychedelic microdosing: netnographic study of Youtube\u2122 videos and on-going research projects","volume":"6","author":"Hupli","year":"2019","journal-title":"Performance Enhancement and Health"},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110402_bib34","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/ijnp\/pyz029","article-title":"Motives and side-effects of microdosing with psychedelics among users","volume":"22","author":"Hutten","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110402_bib35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.euroneuro.2020.10.002","article-title":"Mood and cognition after administration of low LSD doses in healthy volunteers: a placebo controlled dose-effect finding study","volume":"41","author":"Hutten","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110402_bib37","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-024-06665-y","article-title":"Retraction Note: long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials","author":"Jerome","year":"2024","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2025.110402_bib39","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110402_bib40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1455072517753339","article-title":"Powerful substances in tiny amounts: an interview study of psychedelic microdosing","volume":"35","author":"Johnstad","year":"2018","journal-title":"Nordic Studies on Alcohol And Drugs"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110402_bib41","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/1455072520963787","article-title":"Who is the typical psychedelics user? Methodological challenges for research in psychedelics use and its consequences","volume":"38","author":"Johnstad","year":"2021","journal-title":"Nordic Studies on Alcohol And Drugs"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110402_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-81446-7","article-title":"Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing","volume":"11","author":"Kaertner","year":"2021","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110402_bib43","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2025.110402_bib44","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.2147\/NDT.S426193","article-title":"Predicting the intensity of psychedelic-induced mystical and challenging experience in a healthy population: an exploratory post-hoc analysis","volume":"19","author":"Ko","year":"2023","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.neuropharm.2025.110402_bib45","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320950567","article-title":"The therapeutic potential of microdosing psychedelics in depression","volume":"10","author":"Kuypers","year":"2020","journal-title":"THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY"},{"key":"10.1016\/j.neuropharm.2025.110402_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2019.11.008","article-title":"Microdosing psychedelics: motivations, subjective effects and harm reduction","volume":"75","author":"Lea","year":"2020","journal-title":"Int. J. Drug Pol."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110402_bib47","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/02791072.2019.1683260","article-title":"Psychedelic microdosing: a subreddit analysis","volume":"52","author":"Lea","year":"2020","journal-title":"J. Psychoact. Drugs"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110402_bib48","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00213-020-05477-0","article-title":"Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders","volume":"237","author":"Lea","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110402_bib49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/7854_2021_270","article-title":"Dosing psychedelics and MDMA [journal article]","volume":"56","author":"Liechti","year":"2022","journal-title":"Current topics in behavioral neurosciences"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110402_bib50","doi-asserted-by":"crossref","DOI":"10.4088\/PCC.23r03581","article-title":"Modern psychedelic microdosing research on mental health: a systematic review [systematic review journal article]","volume":"26","author":"Lo","year":"2024","journal-title":"The primary care companion for CNS disorders"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110402_bib51","doi-asserted-by":"crossref","DOI":"10.4088\/PCC.23r03581","article-title":"Modern psychedelic microdosing research on mental health: a systematic review","volume":"26","author":"Lo","year":"2024","journal-title":"Prim Care Companion CNS Disord"},{"key":"10.1016\/j.neuropharm.2025.110402_bib52","series-title":"Manual for the Depression Anxiety Stress Scales (DASS)","author":"Lovibond","year":"1993"},{"issue":"7\u20139","key":"10.1016\/j.neuropharm.2025.110402_bib53","first-page":"44","article-title":"Self-administration of psilocybin in the setting of treatment-resistant depression [case reports]","volume":"19","author":"Lyons","year":"2022","journal-title":"Innovations in Clinical Neuroscience"},{"key":"10.1016\/j.neuropharm.2025.110402_bib54","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.neulet.2018.11.027","article-title":"Central nervous system circuits that control body temperature","volume":"696","author":"Madden","year":"2019","journal-title":"Neurosci. Lett."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110402_bib55","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.neuropharm.2011.02.006","article-title":"An animal model of schizophrenia based on chronic LSD administration: old idea, new results","volume":"61","author":"Marona-Lewicka","year":"2011","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110402_bib56","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/02698811211050556","article-title":"Psilocybin microdosing does not affect emotion-related symptoms and processing: a preregistered field and lab-based study","volume":"36","author":"Marschall","year":"2022","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110402_bib57","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/brainsci8030047","article-title":"Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives","volume":"8","author":"Martinotti","year":"2018","journal-title":"Brain Sci."},{"key":"10.1016\/j.neuropharm.2025.110402_bib58","series-title":"Educational and Industrial Testing Services","article-title":"Manual for the profile of mood states","author":"McNair","year":"1971"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110402_bib59","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamapsychiatry.2023.0099","article-title":"Studying harms is key to improving psychedelic-assisted therapy\u2014participants call for changes to research landscape","volume":"80","author":"McNamee","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110402_bib60","article-title":"Psychedelic drug microdosing practices: a qualitative online exploration","author":"Miller","year":"2024","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.neuropharm.2025.110402_bib61","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-024-06666-x","article-title":"Retraction Note: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials","author":"Mithoefer","year":"2024","journal-title":"Psychopharmacology (Berl)"},{"issue":"20","key":"10.1016\/j.neuropharm.2025.110402_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12206519","article-title":"Biomarkers of postpartum depression: a narrative review","volume":"12","author":"Modzelewski","year":"2023","journal-title":"J. Clin. Med."},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110402_bib63","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110402_bib64","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.biopsych.2023.03.013","article-title":"Acute mood-elevating properties of microdosed lysergic acid diethylamide in healthy volunteers: a home-administered randomized controlled trial","volume":"94","author":"Murphy","year":"2023","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110402_bib65","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00213-021-05991-9","article-title":"Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults","volume":"239","author":"Murray","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110402_bib66","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br. Med. J."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110402_bib67","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","article-title":"The pharmacology of lysergic acid diethylamide: a review","volume":"14","author":"Passie","year":"2008","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.neuropharm.2025.110402_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1217102","article-title":"Keeping the promise: a critique of the current state of microdosing research","volume":"15","author":"Petranker","year":"2024","journal-title":"Front. Psychiatr."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110402_bib69","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/0269881120953994","article-title":"Microdosing psychedelics: subjective benefits and challenges, substance testing behavior, and the relevance of intention","volume":"36","author":"Petranker","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110402_bib70","doi-asserted-by":"crossref","DOI":"10.1177\/00221678221075076","article-title":"Microdosing as a response to the meaning crisis: a qualitative analysis","author":"Petranker","year":"2022","journal-title":"J. Humanist. Psychol."},{"key":"10.1016\/j.neuropharm.2025.110402_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104706","article-title":"The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field","volume":"139","author":"Polito","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2025.110402_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104706","article-title":"The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field","volume":"139","author":"Polito","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110402_bib73","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1177\/02698811241254831","article-title":"Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research","volume":"38","author":"Polito","year":"2024","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110402_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211023","article-title":"A systematic study of microdosing psychedelics","volume":"14","author":"Polito","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110402_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211023","article-title":"A systematic study of microdosing psychedelics","volume":"14","author":"Polito","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110402_bib76","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/0269881120940937","article-title":"A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers","volume":"35","author":"Ramaekers","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110402_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.115880","article-title":"Safety and risk assessment of psychedelic psychotherapy: a meta-analysis and systematic review","volume":"335","author":"Romeo","year":"2024","journal-title":"Psychiatry Res."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110402_bib78","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1177\/0269881120908004","article-title":"Microdosing psychedelics: demographics, practices, and psychiatric comorbidities","volume":"34","author":"Rosenbaum","year":"2020","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110402_bib79","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-023-04628-9","article-title":"Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health","volume":"23","author":"Ryan","year":"2023","journal-title":"BMC Psychiatry"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110402_bib80","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/02698811211069100","article-title":"Adverse effects of psychedelics: from anecdotes and misinformation to systematic science","volume":"36","author":"Schlag","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110402_bib81","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.62878","article-title":"Self-blinding citizen science to explore psychedelic microdosing","volume":"10","author":"Szigeti","year":"2021","journal-title":"Elife"},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110402_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/biom11121914","article-title":"5-HT receptors and temperature homeostasis","volume":"11","author":"Voronova","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.neuropharm.2025.110402_bib84","series-title":"Global Drug Survey (GDS) 2020 Psychedelics Key Findings Report","author":"Winstock","year":"2021"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110402_bib85","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1007\/s43440-023-00539-4","article-title":"Cardiovascular safety of psychedelic medicine: current status and future directions","volume":"75","author":"Wsol","year":"2023","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.neuropharm.2025.110402_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1183740","article-title":"Psychedelic therapy in the treatment of addiction: the past, present and future","volume":"14","author":"Zafar","year":"2023","journal-title":"Front. Psychiatr."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110402_bib88","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr. Scand."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082500108X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082500108X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T12:31:05Z","timestamp":1742733065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839082500108X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":84,"alternative-id":["S002839082500108X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110402","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110402","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110402"}}